View the mentioned paper here:

Memantine to Treat Social Impairment in Youths With Autism Spectrum Disorder
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2839518

Access the mentioned course here:

Understanding Autism Spectrum Disorder: A Comprehensive Guide to Clinical Assessment & Diagnosis
https://psychscene.co/4zXOHNW

In this video, Dr Sanil Rege examines a 2025 randomised controlled trial of memantine for social impairment in young people with Autism Spectrum Disorder (ASD).

He explores whether memantine can improve social functioning and outlines how glutamatergic dysregulation, NMDA receptor modulation, and elevated anterior cingulate glutamate may help identify a biologically responsive subtype. He also considers how this may move the field beyond viewing autism as a single, uniform condition.

This session provides clinicians with a neurobiological framework for understanding autism through biomarkers, circuit dysfunction, and emerging precision psychiatry principles.

Chapters:
- Memantine for Social Impairment in Autism
- Why Autism May Not Be One Uniform Condition
- Trial Design and Participant Profile
- pGACC Glutamate as a Biomarker
- Response Rates and Subgroup Findings
- NMDA Receptors and Glutamatergic Mechanisms
- Memantine Versus Ketamine
- From Autism Spectrum to Neurobiological Subtypes

#Autism #Memantine #Psychiatry